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ously diagnosed lymphoma or leukemia. Symptoms of NLIntroduction
Neurolymphomatosis (NL) is a rare disease that can be caused
by T cell, B cell or natural killer cell (NK) lymphomas, but
most commonly by B cell lymphomas.1 NL is characterized
by direct inﬁltration of the central nervous system (CNS),
nerve roots/plexus or peripheral nerves by a hematological
malignancy.2–4 Multiple nerve involvement is more  common
than single nerve involvement.1 Secondary NL occurs as
relapse or the progression of lymphomas.5
Case  report
A 67-year-old male with a history of hepatic transplant in
2002 and under treatment with immunosuppressive agents
(entecavir and everolimus), received the diagnosis of a dif-
fuse large B-cell lymphoma (DLBCL) in May 2014 (lymph node
conglomerate in the right armpit). The patient was treated
with ﬁve cycles of rituximab plus cyclophosphamide, doxo-
rubicin, vincristine and prednisone (R-CHOP). In September,
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reserved.at the end of the treatment, the patient was admitted to
an urgent care facility with left frontotemporal headaches
related to eye and facial pain (V1 and V2 territory), as
well as diplopia. Magnetic resonance imaging (MRI) showed
parenchymal and pachymeningeal involvement in right tem-
poral region, leptomeningeal thickening and enhancement of
the oculomotor, trigeminal, facial, and vestibulocochlear cra-
nial nerves (Figure 1). Cerebrospinal ﬂuid (CSF) cytology was
negative. The patient and the family refused the option of CNS
biopsy, but opted for palliative radiotherapy in order to control
the headache. The patient died in November 2014.
Discussion
Primary NL is deﬁned by neurological involvement as
the initial manifestation of a hematological malignancy.
Secondary NL occurs as relapse or progression of previ-
5ferino Vaz, 13076008 Campinas, SP, Brazil.
include sensorimotor deﬁcits, muscular atrophy, hypoto-
nia, hyporeﬂexia, spontaneous pain, headaches and cranial
nerve dysfunction.2–4 The differential diagnoses include
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Figure 1 – (A) Coronal T1-weighted magnetic resonance imaging after gadolinium administration showing right temporal
leptomeningeal, parenchymal (arrow) and pachymeningeal enhancement; (B) diffusion weighted image with hyperintensity
and (C) apparent diffusion coefﬁcient map  with hypointensity (arrow), conﬁrming restricted diffusion; (D) axial T1-weighted
magnetic resonance imaging after gadolinium administration, showing abnormal enhancement in the left facial nerve
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erve damage from herpes zoster, chemotherapy, inﬂam-
atory neuropathy, drug-induced neuropathy, nerve root
ompression, radiotherapy, lymphoma-associated vasculitis,
nd paraneoplastic syndromes.1,6 A high index of suspicion is
equired due to the variety of symptoms and a large number
f differential diagnoses that must be considered. NL is often
isdiagnosed or undiagnosed due to its rarity and complex
linical manifestations.1,5
Diffuse inﬁltration of cranial nerves is the least common
etastatic clinical presentation of NL.2–4 Ten percent of all
etastatic nervous system lymphomas manifest as NL.3 In
his article, we  describe a rare case of secondary DLBCL with
eptomeningeal and multiple cranial nerve involvement in an
mmunocompromised patient.
Magnetic resonance imaging (MRI) of NL includes abnor-
al  enhancement of the leptomeninges, cranial nerves, or
he periventricular region.7 The radiographic MRI  appearance
f NL includes contrast enhancement of peripheral nerves
ften with enlargement and nodularity. Involved nerves are
sointense on T1-weighted MRI  and hyperintense due to
ncreased signal on short inversion time inversion recovery
STIR) and T2-weighted MRI.3 Leptomeningeal, subependy-
al, dural, or cranial nerve enhancement are ﬁndings
uggestive of leptomeningeal metastases in neuroimaging
ests.8 MRI  contrast is the imaging technique of choice to
etect leptomeningeal metastasis. Computerized tomography
CT) is less sensitive.8 Parenchymal metastases originat-
ng from non-Hodgkin lymphoma often appear as single or
ultiple enhanced lesions and may be accompanied by lep-
omeningeal metastases.8
Tumors are frequently more  cellular than the tissue
rom which they originate therefore, they exhibit relatively
igh signal intensity and restricted diffusion is common for
NS lymphoma lesions.4,5 In MRI  diffusion-weighted images,
NS lymphomas usually present a low apparent diffusion
oefﬁcient (ADC), featuring diffusion restriction.9 Involve-
ent of cranial nerves can be seen, but this is relatively
nfrequent.9 When cranial nerves are affected, MRI typically
hows enhancement of affected nerves, so it is the most used
ethod to corroborate the diagnosis of NL.4In cases with an appropriate clinical context, MRI  with
gadolinium is, by itself, adequate to establish the diagnosis of
leptomeningeal metastasis.3 Nerve biopsy remains the gold
standard in the diagnosis of NL, but it is not usually per-
formed if noninvasive techniques are sufﬁcient for diagnosis2.
Positron emission tomography-computed tomography (PET-
CT) is better than MRI and can often elucidate the diagnosis
of NL when other diagnostic modalities are indeterminate.1,6
Cerebrospinal ﬂuid examinations are not highly sensitive to
diagnose NL. In a series of 96 patients with CNS  lymphoma,
12 had MRI ﬁndings suggestive of leptomeningeal involve-
ment, but only seven of these patients (58.3%) had positive CSF
cytology.4 The diagnosis of secondary neurolymphomatosis
was reached based on clinical data and MRI  ﬁndings.
The prognosis of NL varies greatly among patients. The
overall prognosis of patients with DLBCL has improved
signiﬁcantly with the addition of rituximab to the CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisone)
regimen.10 Patients with lymphoma and NL have an overall
median survival of 21 months and 15 months after the onset of
NL symptoms.2 Treatment of NL is unsatisfactory and patients
have poor outcome. The patient died two  months after the
beginning of NL symptoms. Currently, intravenous methotrex-
ate is the ﬁrst line therapy to treat NL due to its penetration
of the blood–brain barrier. Additional treatments may be com-
bined depending on the distribution and extent of disease.2
NL is an increasingly recognized complication of non-
Hodgkin lymphoma and leukemia in patients undergoing
therapy and its incidence is increasing worldwide, mainly due
to increased awareness of this condition and early detection
by more  sophisticated diagnostic techniques.2 Early clinical
recognition and treatment of NL, permits palliation and poten-
tially retards neurological disease progression.3
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